Breast Cancer Clinical Trial
Official title:
Motiva Flora® Tissue Expander as a Support for the Creation of an Autologous Adipose Matrix for Hybrid Breast Reconstruction: a Pivotal Study
NCT number | NCT06146231 |
Other study ID # | CIP-001000 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 18, 2023 |
Est. completion date | April 2027 |
The present study will be based on a hybrid breast reconstruction approach with initial skin expansion using the Motiva Flora® Tissue Expander followed by a serial fat grafting session and a final step that includes the placement of a permanent breast implant Ergonomix2®.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | April 2027 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Genetically female, aged 18 years or older. 2. Subjects who had provided written informed consent form. 3. The participant needs tissue expansion as part of breast reconstruction treatment, which may include immediate reconstruction. 4. Clinical condition to allow reverse expansion breast reconstruction, at the investigator's discretion. 5. Sufficient fat in donor sites (abdomen, gluteus, hips, and thighs) per plastic surgeon criteria. 6. Complete radiotherapy and chemotherapy at least one year before surgery. 7. BMI between 18.5 and 30.0 (average classified weight). 8. Physical and cognitive capacity to understand and follow the surgeon's recommendations. 9. To be able and willing to comply with all study requirements, including attending follow-up appointments. Only Sub study participants 10. Provide additional consent to undergo an MRI with contrast. Exclusion Criteria: 1. Current pregnancy or lactation, or full-term pregnancy or lactation at any point during the clinical investigation. 2. Abnormal hematological and biochemical values after chemotherapy. 3. High surgical risk according to the investigator. 4. Breast width larger than 18 cm 5. Tumor residues in or near the area where tissue expansion is performed. 6. Subjects with metastatic breast cancer 7. Significant Breast ptosis or poor skin quality 8. Participants who do not have adequate tissue at the intended site for expansion, at the surgeon's discretion, due to previous radiotherapy, ulceration, vascular involvement, history of impaired wound healing, or mastectomy scar deformity. 9. Inadequate chest wall tissue due to damage caused by radiotherapy, tight skin grafts, or radical resection of the pectoralis major muscle. 10. Current or previous infection in the area where the expansion occurs. 11. Any condition that impedes magnetic resonance imaging (MRI), including implanted metal device, claustrophobia, or other ailments that would prohibit MRI scan. 12. Presence of autoimmune diseases such as lupus or scleroderma, or immunocompromised participants due to immunosuppressive or steroid therapy. 13. History of silicone sensitivity. 14. Active smokers 15. Previous attempts of breast reconstruction 16. Subjects who, in the opinion of the investigator, are considered part of any vulnerable population 17. Subjects with affiliation to the Sponsor, sites or investigators, including relatives. 18. Participants who do not live in the procedure's country make it impossible to assist in follow-up visits. 19. Subjects who are participating in other investigation(s) which may affect the outcomes or ability to comply follow-up requirements of this study |
Country | Name | City | State |
---|---|---|---|
Belgium | Universitair Ziekenhuis Gent | Ghent | |
Colombia | Hospital Universitario San Ignacio | Bogotá | |
Costa Rica | Hospital UNIBE | San José | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Establishment Labs | NAMSA |
Belgium, Colombia, Costa Rica, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total adverse envent rate | This variable will be assessed by the total incidence, seriousness, severity, causal relationship with the device, measure(s) taken for resolution, outcome, and duration of the various adverse events (AEs) reported during the surgery and follow-up period. The incidence of AEs, in terms of percentage, will be evaluated statistically with a 95% confidence interval. The analysis of the AEs will include:
All AEs reported during the time period in which Motiva Flora® TE remains implanted (up to a maximum of 16 months) All AEs reported during the conduct of the whole clinical investigation (reconstruction process and 24 months follow-up) |
46 months | |
Secondary | Surgeon's overall satisfaction | Surgeon's overall satisfaction with reconstruction process and results according to the Global Aesthetic Improvement Scale (GAIS), a 5-point Likert scale: 1) Worse (The appearance is worse than the original condition); 2) No change (The appearance is essentially the same as the original condition); 3) Improved (Obvious improvement in appearance from the initial condition, but a touch-up or retreatment is indicated); 4) Much improved (Marked improvement in appearance from the initial condition, but not completely optimal for this patient. A touch-up would slightly improve the result) and 5) Very much improved (Optimal cosmetic result for the implant in this patient). | 46 months | |
Secondary | Patient's anxiety and depression | Patient's anxiety and depression using the HADS (The Hospital Anxiety Depression Scale) | 46 months | |
Secondary | Patient's satisfaction and quality of life impact | Quality of life and satisfaction levels will be assessed using validated international tool Breast-Q. | 46 months | |
Secondary | Device's performance: Device integrity | Percentage of Tissue Expander devices found without any damage at explantation. | 6-16 months | |
Secondary | Changes in breast volume | Percentage of cases where enlargement of the initial breast volume was achieved after the fat grafting process and changes in vascularity of the filled zone documented. after the fat grafting process. | 46 months | |
Secondary | Changes in breast vascularity | Percentage of cases where changes in vascularity of the filled zone were documented after the fat grafting process. | 46 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |